1. Oramed letter to shareholders. (Accessed 20 February 2023). www.prnewswire.com/news-releases/oramed-letter-to-shareholders-301708155.html
2. Vaxxas raises US$23million (A$34million) to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine Candidate. (Accessed 20 February 2023). www.businesswire.com/news/home/20221205005456/en/Vaxxas-Raises-US23-million-A34-million-to-Clinically-Advance-Needle-Free-Vaccines-Including-a-Next-Generation-COVID-19-Vaccine-Candidate
3. Vaxxas raises $23M for needle-free drug delivery tech. (Accessed 20 February 2023). www.drugdeliverybusiness.com/vaxxas-raises-23m-needle-free-drug-delivery/
4. Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner. (Accessed 20 February 2023). www.ypsomed.com/en-GB/news/news-reader-detail-page/eli-lilly-is-focusing-on-its-successful-drug-portfolio.html
5. Eli Lilly discontinues Ypsomed collaboration to pursue its own U.S. insulin pump offering. (Accessed 20 February 2023). www.drugdeliverybusiness.com/eli-lilly-discontinues-ypsomed-collaboration-insulin-pump/